Inhibition of O-6-methylguanine DNA methyltransferase (MGMT) in solid tumors by lomeguatrib
Sabharwal A. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC)
Fiore F. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC).
Fiore F. et al, (2008), J Clin Oncol, 26
Preliminary results of a Cancer Research UK phase I trial combining the dinitrobenzamide prodrug CB1954 (tretazicar) and the NQO2 substrate EP-0152R (caricotamide)
Sarker D. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
The effect of food on the single dose pharmacokinetics of cediranib
Jayson GC. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
The effect of food on the single dose pharmacokinetics of cediranib.
Jayson GC. et al, (2008), J Clin Oncol, 26
Automated enumeration and characterization of circulating melanoma cells in blood
Rao C. et al, (2008), CANCER RESEARCH, 68
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Blagden SP. et al, (2008), Br J Cancer, 98, 894 - 899
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
Hauschild A. et al, (2008), Cancer, 112, 982 - 994
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Midgley RS. et al, (2007), Ann Oncol, 18, 2025 - 2029
Phase I study of nemorubicin hydrochloride (nemorubicin), a novel DNA-intercalator, in combination with cisplatin in patients with unresectable hepatocellular carcinoma (HCC)
Izzo F. et al, (2007), MOLECULAR CANCER THERAPEUTICS, 6, 3380S - 3380S
The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors.
Khan O. and Middleton MR., (2007), Expert Opin Investig Drugs, 16, 1573 - 1584
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer
Sabharwal A. et al, (2007), JOURNAL OF CLINICAL ONCOLOGY, 25
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Ranson M. et al, (2007), J Clin Oncol, 25, 2540 - 2545
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study
Steward WP. et al, (2007), Annals of Oncology, 18, 1098 - 1103
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H. et al, (2006), Ann Oncol, 17, 1835 - 1841
High-risk melanoma with nodal involvement in a young woman.
Khan O. and Middleton M., (2006), Nat Clin Pract Oncol, 3, 517 - 521
Cancer - Identifying and overcoming resistance to treatment - Editorial overview
Kerr D. and Middleton M., (2006), CURRENT OPINION IN PHARMACOLOGY, 6, 321 - 322
Cancer. Identifying and overcoming resistance to treatment
Kerr D. and Middleton M., (2006), Current Opinion in Pharmacology, 6, 321 - 322